A variety of gene therapeutic approaches have begun to be developed to combat human immunodeficiency virus type I (HIV-1) infections. One classical conception of intracellular immunization is to express in the host a mutant form of a viral protein which can interfere with the replication of the virus. We now propose novel methodologies in the development of new intracellular immunization techniques against HIV-1 replication. The isolated immunoglobulin variable regions (light and heavy chains) of monoclonal antibodies directed against select HIV-1 proteins will be directly cloned, utilizing reverse transcriptase-initiated polymerase chain reactions (RT-PCR), from hybridoma cell-lines. Single chain variable regions (SFv) (or single chain antibodies) will be constructed, using designed linker peptides. SFv moieties incorporate the complete antigen- binding domain (Fv) into a single polypeptide. Preliminary data are presented in which an anti-Rev SFv molecule is cloned and expressed in bacteria, as well as in mammalian cells. This anti-Rev SFv, when intracellularly expressed, is demonstrated to have potent anti-HIV-1 activity. Anti-HIV-1 SFv molecules will be constructed against select HIV-1-encoded proteins (e.g., Tat, Rev, Integrase, Gag - p24 and - p17), binding affinities will be evaluated in vitro and the constructs will be intracellularly expressed, with and without nuclear localization signals, in various target cell-types. The SFvs' anti-HIV-1-activities will be evaluated. In addition, retroviral shuttle vectors and adeno-associated virus vectors will be developed to efficiently transduce these SFv moieties into specific cells. Importantly, in collaborative efforts, studies using various anti-HIV-1 SFv moieties in primary CD4-positive PBMC, bone marrow stem cells and thymocytes, ex vivo, will be highlighted. These efforts will focus on inhibition of low passage primary HIV-1 isolates, as model systems for genetic therapy of HIV-1 infection in humans, utilizing targeted SFv constructs. Systems for constitutive and inducible expression of intracellular SFv molecules will be explored. Finally, the severe combined immunodeficiency mouse reconstituted with human peripheral blood lymphocytes (Human - PBL-SCID mouse) will be used as an in vivo model to assess the efficacy of anti-HIV-1 SFv molecules, expressed intracellularly, as a therapeutic modality against HIV-1 infection. Thus, the exquisite binding specificity and nearly limitless diversity of monoclonal antibodies will be brought to bear in gene therapy against HIV-1.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
1R01AI036552-01
Application #
2072897
Study Section
Special Emphasis Panel (SRC (40))
Project Start
1994-09-01
Project End
1998-05-31
Budget Start
1994-09-01
Budget End
1995-05-31
Support Year
1
Fiscal Year
1994
Total Cost
Indirect Cost
Name
Thomas Jefferson University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
061197161
City
Philadelphia
State
PA
Country
United States
Zip Code
19107
Kubota, S; Copeland, T D; Pomerantz, R J (1999) Nuclear and nucleolar targeting of human ribosomal protein S25: common features shared with HIV-1 regulatory proteins. Oncogene 18:1503-14
Jiang, A; Fisher, H; Pomerantz, R J et al. (1999) A genetically engineered spleen necrosis virus-derived retroviral vector that displays the HIV type 1 glycoprotein 120 envelope peptide. Hum Gene Ther 10:2627-36
Kubota, S; Pomerantz, R J (1998) A cis-acting peptide signal in human immunodeficiency virus type I Rev which inhibits nuclear entry of small proteins. Oncogene 16:1851-61
Ho, W Z; Lai, J P; Bouhamdan, M et al. (1998) Inhibition of HIV type 1 replication in chronically infected monocytes and lymphocytes by retrovirus-mediated gene transfer of anti-Rev single-chain variable fragments. AIDS Res Hum Retroviruses 14:1573-80
Inouye, R T; Du, B; Boldt-Houle, D et al. (1997) Potent inhibition of human immunodeficiency virus type 1 in primary T cells and alveolar macrophages by a combination anti-Rev strategy delivered in an adeno-associated virus vector. J Virol 71:4071-8
Duan, L; Zhu, M; Ozaki, I et al. (1997) Intracellular inhibition of HIV-1 replication using a dual protein- and RNA-based strategy. Gene Ther 4:533-43
Pilkington, G R; Duan, L; Zhu, M et al. (1996) Recombinant human Fab antibody fragments to HIV-1 Rev and Tat regulatory proteins: direct selection from a combinatorial phage display library. Mol Immunol 33:439-50
Zhu, M; Duan, L; Pomerantz, R J (1996) TAR- and Tat-independent replication of human immunodeficiency virus type 1 in human hepatoma cells. AIDS Res Hum Retroviruses 12:1093-101
Levy-Mintz, P; Duan, L; Zhang, H et al. (1996) Intracellular expression of single-chain variable fragments to inhibit early stages of the viral life cycle by targeting human immunodeficiency virus type 1 integrase. J Virol 70:8821-32
Mukhtar, M; Duan, L; Bagasra, O et al. (1996) Evaluation of relative promoter strengths of the HIV-1-LTR and a chimeric RSV-LTR in T lymphocytic cells and peripheral blood mononuclear cells: promoters for anti-HIV-1 gene therapies. Gene Ther 3:725-30

Showing the most recent 10 out of 20 publications